MX2021001165A - Agonistas sesgados de interferon-gamma. - Google Patents

Agonistas sesgados de interferon-gamma.

Info

Publication number
MX2021001165A
MX2021001165A MX2021001165A MX2021001165A MX2021001165A MX 2021001165 A MX2021001165 A MX 2021001165A MX 2021001165 A MX2021001165 A MX 2021001165A MX 2021001165 A MX2021001165 A MX 2021001165A MX 2021001165 A MX2021001165 A MX 2021001165A
Authority
MX
Mexico
Prior art keywords
gamma
ifn
methods
mediated
interferon
Prior art date
Application number
MX2021001165A
Other languages
English (en)
Spanish (es)
Inventor
Juan Luis Mendoza
Kenan Christopher Garcia
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2021001165A publication Critical patent/MX2021001165A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MX2021001165A 2018-07-30 2019-07-29 Agonistas sesgados de interferon-gamma. MX2021001165A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862712128P 2018-07-30 2018-07-30
PCT/US2019/043977 WO2020028275A1 (en) 2018-07-30 2019-07-29 Interferon-gamma biased agonists

Publications (1)

Publication Number Publication Date
MX2021001165A true MX2021001165A (es) 2021-07-15

Family

ID=69230882

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021001165A MX2021001165A (es) 2018-07-30 2019-07-29 Agonistas sesgados de interferon-gamma.

Country Status (7)

Country Link
US (1) US12410226B2 (enExample)
EP (1) EP3830115A4 (enExample)
JP (2) JP2021531814A (enExample)
AU (1) AU2019313339A1 (enExample)
CA (1) CA3108066A1 (enExample)
MX (1) MX2021001165A (enExample)
WO (1) WO2020028275A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020028275A1 (en) 2018-07-30 2020-02-06 The Board Of Trustees Of The Leland Stanford Junior University Interferon-gamma biased agonists
CN117242090A (zh) 2021-03-30 2023-12-15 希望之城公司 CAR T细胞疗法和IFNγ

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JPS6124599A (ja) 1984-07-11 1986-02-03 Kyowa Hakko Kogyo Co Ltd 新規ヒトインタ−フエロン−ｒポリペプチド誘導体
US4845196A (en) 1985-06-24 1989-07-04 G. D. Searle & Co. Modified interferon gammas
JP2969461B2 (ja) * 1988-07-23 1999-11-02 株式会社林原生物化学研究所 ヒトγ−インターフェロンとその製造方法並びに用途
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
DE19535853C2 (de) 1995-09-18 1999-04-01 Fraunhofer Ges Forschung Varianten des rekombinanten humanen Interferon-gamma, Verfahren zu ihrer Herstellung und ihre Verwendung
CA2390292A1 (en) * 1999-11-12 2001-05-25 Maxygen Holdings Ltd. Interferon gamma conjugates
US7038015B2 (en) * 2001-04-06 2006-05-02 Maxygen Holdings, Ltd. Interferon gamma polypeptide variants
MXPA03011793A (es) 2001-06-29 2004-04-02 Maxygen Holdings Ltd Formulaciones de interferon.
CA2491178A1 (en) * 2002-07-03 2004-01-15 Maxygen Holdings Ltd. Full-length interferon gamma polypeptide variants
WO2006120580A2 (en) 2005-05-04 2006-11-16 Nautilus Biotech Modified interferon-gamma polypeptides and methods for using modified interferon-gamma polypeptides
WO2008076933A2 (en) 2006-12-14 2008-06-26 Bolder Biotechnology, Inc. Long acting proteins and peptides and methods of making and using the same
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
CA2809747C (en) * 2010-08-30 2018-05-01 Roberto Testi Compositions and methods for treating friedreich's ataxia with interferon gamma
WO2014106843A2 (en) * 2013-01-01 2014-07-10 Inuitive Ltd. Method and system for light patterning and imaging
WO2018077893A1 (en) 2016-10-24 2018-05-03 Orionis Biosciences Nv Targeted mutant interferon-gamma and uses thereof
WO2020028275A1 (en) 2018-07-30 2020-02-06 The Board Of Trustees Of The Leland Stanford Junior University Interferon-gamma biased agonists
US20220000921A1 (en) * 2018-11-20 2022-01-06 Innovative Cellular Therapeutics Holdings, Ltd. Modified Cell Expressing Therapeutic Agent and Uses thereof

Also Published As

Publication number Publication date
CA3108066A1 (en) 2020-02-06
EP3830115A1 (en) 2021-06-09
US12410226B2 (en) 2025-09-09
JP2021531814A (ja) 2021-11-25
EP3830115A4 (en) 2022-08-10
WO2020028275A1 (en) 2020-02-06
US20210309707A1 (en) 2021-10-07
JP2024137947A (ja) 2024-10-07
AU2019313339A1 (en) 2021-03-11

Similar Documents

Publication Publication Date Title
MX2021013197A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
CL2021001823A1 (es) Amidas de pirrolidina iii sustituidas
CR20110520A (es) Acetamidas sustituidas por n-(hetero)-arilo y 2-(hetero)-arilo para usarse como moduladoras de la señalización de wnt
CL2020000375A1 (es) Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre.
CO2020006248A2 (es) Moduladores de la vía de estrés integrada
ECSP20027553A (es) Moduladores de la vía de estrés integrada
ECSP18060342A (es) Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos
MX389514B (es) Compuestos útiles como moduladores de canal receptor 8 de potencial transitorio de melastatina (trpm8).
CR20160321A (es) Modulares de tetrahidropiridopirazinas de gpr6
JO3719B1 (ar) 4- أوكسو-4،3- داي هيدرو-3،2،1- بنزوترايازينات كمواد ضابطة لأجل gpr139
NI201900076A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
BR112017019305A2 (pt) compostos cíclicos terapêuticos como imunomoduladores
HN2011002272A (es) Derivados de indol como antagonistas del receptor crth2
ECSP13012410A (es) Composiciones y métodos para modular la vía de señalización de wnt
MX2021015632A (es) Moduladores del receptor arilo y metodos para elaborar y usar los mismos.
CR20110103A (es) Heteroarilos sustituidos
ECSP19055179A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
CO2021016003A2 (es) Amidas de pirazolo-piridina sustituidas y su uso como moduladores del receptor glun2b
AR114517A1 (es) Transmisión de uci urllc
UY33118A (es) Indazoles aminotiazolona sustituidos como moduladores del receptor a relacionado con estrógenos
MX2021001165A (es) Agonistas sesgados de interferon-gamma.
CL2022001646A1 (es) Tiofeno carboxamidas sustituidas y sus derivados como microbicidas
CR20140424A (es) Compuestos de cromano sustituidos como moduladores del receptor sensible al calcio
EA200970662A1 (ru) Трициклические соединения и их применение в качестве модуляторов глюкокортикоидного рецептора
CL2021003127A1 (es) Durmientes ferroviarios y métodos de los mismos.